Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous...
Khan F., Rahman A., Carrier M., Kearon C., Weitz J. I., Shul`man S., Couturaud F., Eichinger S., Kyrle P. A., Becattini C., Agnelli G., Brighton T. A., Lensing A. W. A., Prins M. H., Sabri E., Hutton B., Pinede L., Cushman M., Palareti G., Wells G. A., Prandoni P., Büller H. R., Rodger M. A.
BMJ: British Medical Journal: International Edition
Vol.366, Num.l4363
Опубликовано: 2019
Тип ресурса: Статья
Аннотация:
To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years. Design Systematic review and meta-analysis. Data sources Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019). Study selection Randomised controlled trials and prospective cohort studies reporting symptomatic recurrent VTE after discontinuation of anticoagulant treatment in patients with a first unprovoked VTE event who had completed at least three months of treatment. Data extraction and synthesis Two investigators independently screened studies, extracted data, and appraised risk of bias. Data clarifications were sought from authors of eligible studies. Recurrent VTE events and person years of follow-up after discontinuation of anticoagulant treatment were used to calculate rates for individual
Ключевые слова:
anticoagulant agent; anticoagulant agent; anticoagulant therapy; Article; case fatality rate; clinical decision making; deep vein thrombosis; follow up; human; lung embolism; meta analysis; morbidity; parent counseling; practice guideline; priority journal; prognosis; quality control; randomized controlled trial (topic); recurrence risk; recurrent disease; systematic review; treatment duration; venous thromboembolism; pathophysiology; procedures; recurrent disease; risk assessment; time; treatment withdrawal; venous thromboembolism; Anticoagulants; Humans; Recurrence; Risk Assessment; Time; Venous Thromboembolism; Withholding Treatment
Язык текста: Английский
ISSN: 0959-8146
Khan F.
Rahman A.
Carrier M.
Kearon C.
Weitz J. I.
Shul`man S. Se`m 1952-
Couturaud F.
Eichinger S.
Kyrle P. A.
Becattini C.
Agnelli G.
Brighton T. A.
Lensing A. W. A.
Prins M. H.
Sabri E.
Hutton B.
Pinede L.
Cushman M.
Palareti G.
Wells G. A.
Prandoni P.
Büller H. R.
Rodger M. A.
Хан Ф.
Рахман А.
Cарриер М.
Кеарон C.
Wеитз Й. И.
Шульман С. Сэм 1952-
Cоутюрауд Ф.
Еичингер С.
Кyрле П. А.
Беcаттини C.
Агнелли Г.
Бригхтон Т. А.
Ленсинг А. W. А.
Принс М. Х.
Сабри Е.
Хуттон Б.
Пинеде Л.
Cушман М.
Паларети Г.
Wеллс Г. А.
Прандони П.
Бüллер Х. Р.
Родгер М. А.
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: Systematic review and meta-analysis
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous...
Текст визуальный непосредственный
BMJ: British Medical Journal: International Edition
BMJ Publishing Group
Vol.366 Num.l4363
2019
Статья
anticoagulant agent anticoagulant agent anticoagulant therapy Article case fatality rate clinical decision making deep vein thrombosis follow up human lung embolism meta analysis morbidity parent counseling practice guideline priority journal prognosis quality control randomized controlled trial (topic) recurrence risk recurrent disease systematic review treatment duration venous thromboembolism pathophysiology procedures recurrent disease risk assessment time treatment withdrawal venous thromboembolism Anticoagulants Humans Recurrence Risk Assessment Time Venous Thromboembolism Withholding Treatment
To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years. Design Systematic review and meta-analysis. Data sources Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019). Study selection Randomised controlled trials and prospective cohort studies reporting symptomatic recurrent VTE after discontinuation of anticoagulant treatment in patients with a first unprovoked VTE event who had completed at least three months of treatment. Data extraction and synthesis Two investigators independently screened studies, extracted data, and appraised risk of bias. Data clarifications were sought from authors of eligible studies. Recurrent VTE events and person years of follow-up after discontinuation of anticoagulant treatment were used to calculate rates for individual